Immunocore

Immunocore

Primary Menu

  • About us
    • Management Team
    • Board of Directors
    • Partners
  • Our science
    • Pipeline
    • Publications
    • Scientific Advisory Board
  • Our therapy areas
    • Oncology
    • Infectious Diseases
    • Autoimmune and Inflammation Diseases
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us

Primary Menu

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us
  1. Home
  2. /
  3. News

News

  • 19 February 2021

    Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
  • 16 February 2021

    Immunocore announces key appointments to management and Board
  • 9 February 2021

    Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement
  • 5 February 2021

    Immunocore Announces Pricing of Upsized Initial Public Offering
  • 11 January 2021

    Immunocore announces closing of $75.0 Million Series C round
  • 3 December 2020

    Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
  • 23 November 2020

    Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
  • 15 October 2020

    Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director
  • 27 August 2020

    Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
  • 26 May 2020

    Immunocore announces dosing of first patient with fourth ImmTAC
  • ← Previous
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 11
  • Next →

Sign up to receive news email alerts

News archive
  • Show all
  • 2021 (5)
  • 2020 (8)
  • 2019 (13)
  • 2018 (10)
  • 2017 (13)
  • 2016 (11)
  • 2015 (20)
  • 2014 (6)
  • 2013 (11)
  • 2012 (3)
  • 2011 (1)
  • 2010 (4)
  • 2009 (1)
  • 2008 (1)

Immunocore

Immunocore
  • About us
  • Our science
  • Our therapy areas
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd